panzyga® is a treatment for people with certain immune system disorders.

This website provides:

  • information on immune system disorders and immunoglobulin therapy for the general public
  • resources for patients already prescribed panzyga®
  • product information for healthcare professionals

Patient Information Leaflet (PIL)


Summary of Product Characteristics (SPC)


Assessment Report by Paul Ehrlich Institut (PEI)


Safety Reporting Information for Patients and the Public: This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects you can help provide more information on the safety of this medicine.

Safety Reporting Information for Healthcare Professionals: Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Octapharma by telephoning 0845 1300 522.

Octapharma is a global company that specialises in the development and production of human proteins.

Details of clinical trials sponsored by Octapharma are provided at and

Copyright © 2017 | Octapharma | Legal Statement | Privacy Statement
Octapharma Ltd, The Zenith Building, 26 Spring Gardens, Manchester M2 1AB 
HOME/PAN/01  Date of preparation: 15 March 2019